TABLE 2

Patient Characteristics, Prior Oncologic Therapy, and Trial Outcome

Patient no.	Sex	Age (y)	Cohort	Eastern Cooperative Oncology Group	Primary site	Prior chemotherapy with or without radiotherapy	Sites of disease at study entry	Screening carcinoembryonic antigen	End-of-study carcinoembryonic antigen	Overall response
101	Female	54	1	1	Rectum	NXRT	Liver, lung, LN	2.1	1.4	PD
102	Male	59	1	0	Colon	FX	LN	3.1	3.7	PD
103	Male	59	1	0	Colon	A5FU	LN	258	544	SD
104	Female	69	2	1	Colon	FX, FI, M	Liver, lung, omentum	8.8	861	PD
105	Male	60	2	0	Rectum	NXRT, FX, FI	Liver, lung, LN	462	1,175	PD
106	Male	66	2	0	Colon	A5FU, FX	Liver, pelvis	38	29	SD
107	Female	66	2	0	Rectum	NXRT	Lung, omentum, mesentery	1.6	1.6	SD
108	Male	69	2	0	Colon	FX, hu3S193 (phase I)	Liver, LN	4.7	2.3	PR
109	Male	51	2	0	Colon	FX, FI, M, cetuximab	Lung, LN	27.4	16.6	SD
110	Male	52	3	0	Colon	FX	Liver	11.9	9.3	SD
111	Female	61	3	0	Colon	FX, I	Lung, LN, adrenal	35.6	43.2	SD
112	Female	41	3	0	Rectum	NXRT, FX, FI, C, B	Lung, liver, psoas, paravertebral mass	645	1,386.3	PD
113	Male	58	4	0	Colon	I, FX	Lung, liver	1,005	1,538.3	PD
114	Male	64	4	0	Colon	FX	Suprapubic mass, abdominal wall, bowel	17.9	20.5	SD
115	Male	59	4	0	Colon	FX, I	Lung, liver, LN	15.2	57.4	PD
116	Male	66	5	0	Rectum	NXRT, I	Lung, liver, LN	243.3	408.2	SD
117	Male	66	5	0	Colon	FX	Liver	29.1	16.7	SD
118	Male	48	5	0	Rectum	NXRT	Lung, lymph nodes	42.3	28.1	NA
119	Female	55	5	0	Rectum	FX, FI + C + B	Lung, liver, lymph nodes	NA	183.5	SD

NXRT = neoadjuvant chemoradiation (5FU); LN = lymph nodes; FX = FOLFOX; A5FU = adjuvant 5FU; SD = stable disease; FI = FOLFIRI; M = mitomycin; I = irinotecan; C = cetuximab; B = bevacizumab; NA = not assessable.